lambornk@neurosurg.ucsf.edu
(415) 353-2863 (voice)
(415) 502-5171 (fax)

Box 0372, UCSF; San Francisco, CA 94143-0372

Oberlin College, Oberlin, OH, B.A., 1966, Math
Stanford University, Stanford, CA, M.S., 1968, Statistics
Stanford University, Stanford, CA, Ph.D., 1970, Statistics

Chang SM, Theodosopoulos P, Lamborn KR, Malec M, Rabbitt J, Page M, Prados MD: Temozolomide in the treatment of recurrent malignant glioma. Cancer 100: 605-611, 2004

Keles GE, Lamborn KR, Chang S, Prados MD, Berger MS : The effect of volume of residual disease on outcome in adult patients with recurrent supratentorial glioblastoma multiforme undergoing chemotherapy. J Neurosurg 100:41-6, 2004

Papavassiliuo E, Rau G, Heath S, Abosch A, Barbaro N, Larson P, Lamborn K, Starr PA: Thalamic deep brain stimulation for essential tremor: relation of lead location to outcome. Neurosurg 54:1120-30; 2004

Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas KM, Berger MS : Permanent I-125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-Oncology 6:119-125, 2004

Keles GE, Lamborn KR, Chang S, Prados MD, Berger MS : The effect of volume of residual disease on outcome in adult patients with recurrent supratentorial glioblastoma multiforme undergoing chemotherapy. J Neurosurg 100: 41-6, 2004

Chang MS, Lamborn KR, Malec M, Rabbitt J, Page M, Prados MD : Phase II study of salvage therapy with high- dose tamoxifen and oral etoposide for recurrent malignant glioma. Therapy 1:53-60, 2004

Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD : Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Rad Oncol Biol Phys 60:353-357, 2004

Lamborn KR, Chang S, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncology 6:227-235, 2004

Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, Lamborn KR, Deen DF: Anti-tumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-Oncology 6: 218-226, 2004

Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK, Wara WM, Malec M, Rabbitt J, Page M, Chang SM: A Phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Rad Oncol Biol Phys 61: 1454-59, 2005

Wang DF, Ruan H, Hu L, Lamborn KR, Kong EL, Rehemtulla A, Deen DF: Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther 12: 276-83, 2005

Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5914-19, 2005

Chen JK, Hu LJ, Wang J, Lamborn KR, Kong EL, Deen DF: Hypoxia-induced BAX overexpression and radiation killing of hypoxic glioblastoma cells. Radiat Res 163:644-53, 2005

Parsa AT, Wachhorst S, Lamborn KR, Prados MD, Berger MS, Chang SM: Prognostic significance of intracranial dissemination in adult glioblastoma multiforme. J Neurosurg 102: 622-8, 2005

Quinones-Hinojosa A, Lyon R, Zada G, Lamborn KR, Gupta N, Parsa AT, McDermott MW, Weinstein PR: Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection predict severity of postoperative motor deficits. Neurosurgery 56:982-93, 2005

Ozawa T, Hu JL, Hu LJ, Kong E, Bollen AW, Lamborn KR, Deen DF: Functionality of hypoxia-induced BAX expesssion in a human glioblastoma xenograft model. Cancer Gene Ther 12:449-55, 2005

Misra A, Pellarin M, Nigro J, Smirnov I, Moore D, Lamborn KR, Pinkel D, Albertson DG, Feuerstein BG: Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 11:2907-18, 2005.

Ozawa T, Afzal J, Lamborn KR, Bollen AW, Bauer WF, Koo M-S, Kahl SB Deen DF: Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. Int J Rad Onc Bio Phys 63:247-252, 2005.

Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-7, 2005.

Misra A, Pellarin M, Hu L, Kunwar S, Lamborn KR, Deen DF, Feuerstein BG: Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme. Genes Chromosomes Cancer 45: 20-30, 2005.

Lu Y, Jin H, Lamborn KR: A design of Phase II cancer trials using total and complete response endpoints. Stat Med 24:3155-70, 2005.

Cloughesy TF, Kuhn J, Robins IH, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAgelis L, Schiff D, Junck L, Groves M, Writght J, Lamborn K, Sebti S, Prados M: A Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study. J Clin Onc 23:6647-56, 2005.

Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Razier J, Hess K, Aldape K, Lamborn KR, Juhn J, Dancey J, Prados MD: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-61, 2005.

Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD: GNOSIS: Guidelines for neuro-oncology Ð Standards for investigational studies Ð reporting of phase I and phase 2 clinical trials. Neuro-oncol 7:425-34, 2005

Gomez DR, Missett BT, Wara WM, Lamborn KR, Prados MD, chang S, Berger MS, Haas-Kogan DA: High failure rate in spinal ependymomas with long-term follow-up. Neuro-oncol 7: 254-9, 2005.

Lassman AB, Rossi MR, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WKA, Prados M, Holland EC: Molecular study of malignant gliomas treated with the peidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium (NABTC) trials 01-03 and 00-01. Clin Cancer Res 11: 7841-50, 2005.

Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD: Diagnostic, treatment and demographic factors influencing survival in population-based study of adult glioma patients in the San Francisco Bay Area. Neuro-oncol 8: 12-26, 2006

Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbit J, Page M, Fedoroff A, Xie D, Kelley SK: Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 8: 67-78, 2006

Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD: Serum IgE, tumor epidermal growth factor receptor expression and inherited polymorphisms associated with glioma survival. Cancer Res. 8:4531-41, 2006

Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S: Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Human Pathology 3:272-82, 2006

Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 8:189-93, 2006

Mishra KK, Puri DR, Missett BT, Lamborn KR, Prados MD, Berger MS, Banerjee A, Gupta N, Wara WM, Haas-Kogan DA: The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro-oncol 8:166-74, 2006.

12/7/06